Related by context. All words. (Click for frequent words.) 74 metastatic castration resistant 71 prostate cancer CRPC 69 refractory ovarian cancer 69 fallopian tube carcinoma 69 gastrointestinal stromal tumors GIST 69 metastatic malignant 69 cetuximab Erbitux ® 69 metastatic renal cell carcinoma 68 imatinib Gleevec ® 68 leukemia AML 68 recurrent glioblastoma multiforme 68 prostate cancer HRPC 67 hormone refractory metastatic prostate 67 mRCC 67 sorafenib Nexavar 67 cetuximab Erbitux 67 metastatic castrate resistant 67 Myelodysplastic Syndrome MDS 67 cell lymphoma CTCL 67 stage IIIB 67 metastatic colorectal 67 pan HDAC inhibitor 66 huC# DM4 66 erlotinib Tarceva ® 66 refractory chronic myeloid 66 prostate cancer AIPC 66 axitinib 66 assessing T DM1 66 CBLC# 66 EGFR TKI 66 resistant hormone refractory 66 cetuximab Erbitux R 66 evaluating tivozanib 66 castrate resistant prostate cancer 66 Cell Lymphoma 66 oral prodrug 65 5 fluorouracil leucovorin 65 dasatinib Sprycel ® 65 pharmacokinetic PK study 65 recurrent NSCLC 65 Aflibercept 65 pegylated liposomal doxorubicin 65 receptor tyrosine kinase inhibitor 65 Malignant Melanoma 65 II Clinical Trial 65 bevacizumab Avastin 65 Cutaneous T 65 metastatic RCC 65 recurrent glioblastoma 65 Quinamed 65 recurrent metastatic 65 IV NSCLC 65 abacavir Ziagen 65 humanised monoclonal antibody 65 Neoadjuvant 65 Glioblastoma Multiforme 65 fosbretabulin 65 unresectable tumors 65 ovarian carcinoma 65 alvespimycin 65 minimally symptomatic metastatic castrate 65 CYT# potent vascular disrupting 65 demonstrated antitumor activity 64 mitoxantrone plus 64 IL# PE#QQR 64 multiple myeloma MM 64 leukemia CLL 64 BARACLUDE ® 64 metastatic gastric 64 Capesaris 64 depsipeptide 64 generation purine nucleoside 64 LHRH receptor positive 64 sunitinib Sutent ® 64 Zarnestra 64 BRIM2 64 luteinizing hormone releasing 64 Camptosar ® irinotecan 64 Ceflatonin 64 localized renal 64 Sprycel dasatinib 64 trabectedin 64 sunitinib Sutent 64 tumors GIST 64 relapsed MM 64 unresectable stage 64 standard chemotherapy regimen 64 MAGE A3 ASCI 64 AVASTIN 64 advanced metastatic renal 64 severe oral mucositis 64 gefitinib Iressa 64 Femara letrozole 64 Cannabinor 64 prostate carcinoma 64 relapsed ovarian cancer 64 estramustine 64 Camptosar ® 64 pancreatic adenocarcinoma 64 ritonavir boosted 64 Sipuleucel T 64 huN# DM1 64 mCRPC 64 Ophena TM 64 HER2 positive metastatic breast 64 Combination REOLYSIN R 64 Safinamide 64 oral ridaforolimus 64 gastrointestinal stromal tumor GIST 64 imatinib resistant 63 castration resistant prostate cancer 63 Irinotecan 63 pain palliation 63 pertuzumab 63 Trastuzumab 63 Romidepsin 63 thalidomide Thalomid 63 INCB# [003] 63 docetaxel chemotherapy 63 Pharmacokinetics PK 63 5 Fluorouracil 63 Clinical Trial Results 63 FUSILEV enhances 63 phase IIb study 63 mapatumumab 63 docetaxel Taxotere 63 Hormone Refractory Prostate Cancer 63 androgen independent 63 HuMax EGFr 63 gemcitabine Gemzar 63 Randomized Phase 63 erlotinib Tarceva 63 PEGylated Fab fragment 63 cilengitide 63 PROSTVAC VF 63 Advanced Melanoma 63 bevacizumab Avastin ® 63 sipuleucel T 63 docetaxel Taxotere ® 63 metastatic androgen independent 63 Sym# 63 BRAF inhibitor 63 leukemia ALL 63 Proxinium TM 63 Dasatinib 63 nonmetastatic 63 irinotecan doxorubicin oxaliplatin paclitaxel 63 IV melanoma 63 antibody MAb 63 indolent follicular non 63 Epratuzumab 63 Patients Treated With 63 Pemetrexed 63 colorectal cancer liver metastases 63 tanespimycin 63 systemic anaplastic large 63 HGS ETR2 63 Metastatic Prostate Cancer 63 imatinib Gleevec 63 IV malignant melanoma 63 alfa 2a 63 gastrointestinal stromal tumors 63 tyrosine kinase inhibitors TKIs 63 Erlotinib 63 Pivotal Phase III 63 biliary tract cancer 63 Tarceva TM 63 Immunotherapeutic 63 vinca alkaloid 63 metastatic malignant melanoma 63 randomized Phase IIb 63 cisplatin resistant 63 paclitaxel Taxol 63 Kamada AAT 63 compound AEZS 63 Luteinizing Hormone Releasing Hormone 63 Neulasta ® 63 essential thrombocythemia ET 63 Doxil ® 63 Hsp# Inhibitor 63 docetaxel Taxotere R 63 liposomal amphotericin B 63 lexidronam injection 62 Relapsed Refractory 62 Enzastaurin 62 PKC# 62 malignant ascites 62 pediatric malignancies 62 Denufosol 62 Bortezomib 62 Diabetic Macular Edema DME 62 metastatic pancreatic 62 alpha 2a 62 TNF Tumor Necrosis Factor 62 dasatinib Sprycel 62 radiation sensitizer 62 gemcitabine Gemzar ® 62 Gleevec imatinib mesylate 62 Aplidin 62 cutaneous T 62 satraplatin Phase 62 ganetespib 62 KRAS mutations occur 62 Personalized Immunotherapy 62 bevacizumab Avastin R 62 ixabepilone 62 Ophena 62 myelodysplastic myeloproliferative diseases 62 sorafenib tablets 62 metastatic prostate cancer 62 Trial Evaluating 62 Phase 2b Clinical Trial 62 virus HCV protease inhibitor 62 forodesine 62 chemoradiotherapy 62 PROVENGE ® 62 Neuvenge 62 neratinib 62 refractory acute myeloid 62 YONDELIS 62 HGS ETR1 62 Vidaza azacitidine 62 liposomal formulation 62 temsirolimus 62 selective modulator 62 Phase IIIb clinical 62 prostate cancer PCa 62 bortezomib Velcade 62 cell lymphoma ALCL 62 Metastatic Melanoma 62 alkylating agent 62 concurrent chemoradiation 62 Nexavar sorafenib 62 verteporfin 62 cabazitaxel 62 Ozarelix 62 stage IIIb 62 FOLOTYN ® 62 sunitinib malate 62 chimeric monoclonal antibody 62 Albuferon TM 62 GW# [003] 62 EGFR mutant 62 phase IIb clinical 62 Benign Prostatic Hyperplasia BPH 62 epithelial tumors 62 metastatic GIST 62 RAV# 62 PD LID 62 CLL SLL 62 liposomal doxorubicin 62 chronic myeloid 62 Xelox 62 Kinase Inhibitor 62 basiliximab 62 Amrubicin 62 cutaneous melanoma 62 chronic lymphocytic leukemia CLL 62 BCIRG 62 neoadjuvant treatment 62 cisplatin chemotherapy 62 monoclonal antibody conjugated 62 angiogenesis inhibitor 62 ZACTIMA 62 Deforolimus 62 Paraplatin ® 62 PEG IFN 62 galiximab 62 Peginterferon 62 non resectable 62 cell carcinoma RCC 62 Prolongs Survival 62 Phase 2a Clinical Trial 62 basal cell carcinoma BCC 62 Diffuse Large B 62 refractory chronic lymphocytic 62 Azacitidine 62 Folfox 61 Renal Cell Carcinoma 61 Hepatocellular Carcinoma HCC 61 SCCHN 61 ON #.Na 61 Initiate Phase 61 Phase Ib study 61 taxane resistant 61 mTOR inhibitor 61 Soft Tissue Sarcoma 61 adjuvant radiotherapy 61 PNP inhibitor 61 Phase IIb clinical trials 61 BRIM3 61 mCRC patients 61 Tyrima 61 MAGE A3 61 Dose Ranging Study 61 HoFH 61 vidofludimus 61 histone deacetylase inhibitor 61 familial amyloidotic polyneuropathy FAP 61 Tanespimycin 61 recurrent glioblastoma multiforme GBM 61 lapatinib Tykerb 61 Vicriviroc 61 castrate resistant 61 Panzem NCD 61 Randomized Phase II 61 medically inoperable 61 refractory colorectal cancer 61 Annamycin 61 SPRYCEL ® 61 Study Evaluating 61 OHR/AVR# 61 HQK 61 urothelial cancer 61 neoadjuvant 61 multicentre randomized 61 Prostate AdenoCarcinoma Treatment 61 denileukin diftitox 61 Omacetaxine 61 hypereosinophilic syndrome 61 Phase Ib clinical 61 PROSTVAC TM 61 TO AVOID PREGNANCY WHILE 61 Severe Sepsis 61 baminercept 61 gemcitabine carboplatin 61 Chronic Myelogenous Leukemia CML 61 fluvastatin 61 keloid scarring 61 Phase #/#a trial 61 gastric adenocarcinoma 61 invasive candidiasis 61 Cethromycin 61 Fluorouracil 61 bone metastasis 61 Vicinium TM 61 FOLFOX6 61 operable breast cancer 61 adalimumab Humira 61 LBH# 61 multicenter Phase II 61 Meets Primary Endpoint 61 papillary renal cell carcinoma 61 autoantibody positive 61 Bazedoxifene 61 idebenone 61 Temsirolimus 61 IMA# 61 Phase #b/#a clinical 61 Endometrial 61 Adjuvant Treatment 61 Pegylated Interferon 61 Hepatocellular Carcinoma 61 dexpramipexole 61 investigational monoclonal antibody 61 Complicated Skin 61 prostate cancer CaP 61 Toxicities 61 polycythemia vera PV 61 Phase IIb Trial 61 Phase 2b Study 61 KRAS mutant tumors 61 Hodgkin lymphoma NHL 61 panitumumab Vectibix 61 Velcade bortezomib 61 phase IIa 61 Refractory Hodgkin Lymphoma 61 Anti VEGF 61 capecitabine Xeloda 61 Orally administered 61 antibody MT# 61 lymphoma CTCL 61 Ambrisentan 61 Pivotal Trial 61 MyVax R 61 metastatic sarcoma 61 esophageal candidiasis 61 pancreatic carcinoma 61 Elagolix 61 MGd 61 nucleoside analog 61 ThermoDox R 61 metastatic hormone refractory 61 paclitaxel carboplatin 61 TAXOTERE R 61 AEG# 61 multicenter randomized controlled 61 ZD# [001] 61 cisplatin gemcitabine 61 HCV Genotype 61 trastuzumab DM1 61 grade cervical intraepithelial 61 administered subcutaneously 61 evaluating Prochymal 61 lupus nephritis 61 colorectal carcinoma 61 mertansine 61 ALA PDT 61 oblimersen 61 Chronic Myeloid Leukemia 61 B Cell Lymphoma 61 epithelial ovarian 61 anterior uveitis 61 Metastatic Colorectal Cancer 61 evaluating picoplatin 61 Decitabine 61 plus prednisone 61 relapsed ALL 61 vinorelbine 60 ELACYT 60 pancreatic neuroendocrine tumors 60 ara C 60 colon carcinoma 60 heavily pretreated patients 60 MKC# MT 60 Parathyroid Hormone 60 LymphoStat B TM 60 M2 subunit 60 HBeAg negative 60 chronic eosinophilic leukemia 60 dose escalation clinical 60 vandetanib 60 INCB# [001] 60 iclaprim 60 tiuxetan 60 Tesetaxel 60 DAVANAT 60 HER2 antibody 60 Pazopanib 60 milatuzumab 60 superficial basal cell carcinoma 60 PEG SN# 60 Multiple Myeloma MM 60 non resectable metastatic 60 platinum refractory 60 monoclonal anti 60 refractory CML 60 metastatic neuroendocrine tumors 60 relapsed multiple myeloma 60 5 FU leucovorin 60 somatostatin analogue 60 endometrial hyperplasia 60 FASLODEX 60 Idiopathic Pulmonary Fibrosis 60 HuMax CD4 60 Tezampanel 60 beta 1a 60 cutaneous T cell 60 volociximab 60 Phase 2b Trial 60 Preclinical Study 60 non splenectomized 60 Cimzia TM 60 bleomycin 60 Degarelix 60 non nucleoside inhibitor 60 chemotherapy cisplatin 60 dexrazoxane 60 ongoing Phase 1b 60 Myelofibrosis 60 tyrosine kinase inhibitor 60 decitabine 60 ToGA 60 targeted antifolate 60 Zybrestat 60 cediranib 60 situ CIS 60 Peginterferon alfa 2b 60 Interferon Beta 60 trastuzumab Herceptin 60 VELCADE melphalan 60 microwave hyperthermia 60 Phase 1b trial 60 vemurafenib 60 Nilotinib 60 multikinase inhibitor 60 ribavirin RBV 60 HSP# inhibitor 60 Flu Cy 60 chlorambucil 60 tumor xenograft models 60 trastuzumab Herceptin R 60 5-FU/LV 60 stage IIIB IV 60 Tavocept 60 Lupus Nephritis 60 Brentuximab Vedotin SGN 60 Hematologic 60 malignant pleural mesothelioma 60 refractory prostate cancer 60 CD3 monoclonal antibody 60 Taxotere chemotherapy 60 lymphoid malignancies 60 palifermin 60 PRTX 60 doxorubicin Adriamycin 60 Natalizumab 60 Newly Diagnosed Multiple Myeloma 60 atherothrombotic events 60 PANVAC VF 60 syngeneic 60 anti angiogenic agent 60 minimally symptomatic 60 goserelin 60 Vascugel 60 PAOD 60 Cytoxan 60 trastuzumab DM1 T DM1 60 investigational antiplatelet agent 60 IMPACT IMmunotherapy 60 PEGylated interferon beta 1a 60 Factor VIIa 60 Adjuvant Therapy 60 velafermin 60 Antitumor Activity 60 enzastaurin 60 colorectal liver metastases 60 Chronic Hepatitis C 60 Campath alemtuzumab 60 seminoma 60 sodium thiosulfate STS 60 spontaneously regress 60 posaconazole 60 metastatic colorectal carcinoma 60 AAG geldanamycin analog 60 Polymerase Inhibitor 60 CTAP# Capsules 60 OMP #M# 60 Dose Escalation Study 60 Hodgkin lymphoma HL 60 Aurora Kinase 60 Gleevec resistant 60 Fludarabine 60 FOLFOX4 60 Prostatic 60 non metastatic osteosarcoma 60 Demonstrates Potent 60 cyclophosphamide methotrexate 60 Phase Ib II 60 nonsmall cell lung cancer 60 neuroblastoma tumors 60 nilotinib Tasigna ® 60 Kahalalide F 60 metastatic carcinoma 60 torezolid 60 phase IIb 60 myeloproliferative disorders 60 demethylating agent 60 KRN# 60 Bezielle 60 Glufosfamide 60 OMP #R# 60 ZOLINZA 60 Xanafide 60 liver metastasis 60 prostate carcinomas 60 Cetuximab Erbitux 60 EpCAM 60 urothelial carcinoma 60 irinotecan chemotherapy 60 gemcitabine cisplatin 60 FTY# fingolimod 60 Lenalidomide 60 Oral Fingolimod 60 KSP inhibitor 60 investigational humanized monoclonal antibody 60 VEGFR2 inhibitor 60 multi kinase inhibitor 60 Chronic Myeloid Leukemia CML 60 TransVax 60 phase IIb trial 60 AEGR 60 T#I [002] 60 Chronic Lymphocytic Leukemia CLL 60 neoadjuvant therapy 60 Telaprevir VX 60 pharmacokinetic PK 60 Cloretazine ® 60 resistant ovarian cancer 60 endocrine therapies 60 Kit CD# positive 60 Alocrest 60 hormone refractory prostate cancer 60 Phase 1b clinical trials 60 paclitaxel cisplatin 60 Platinol ® 60 intravesical instillation 60 Romiplostim 60 Daclizumab 60 Chronic Lymphocytic Leukemia 60 refractory gout 60 XL# SAR# 60 myelofibrosis MF 60 registrational trial 60 advanced unresectable 60 metastatic renal cell 60 Hydroxyurea 60 Vitaxin 60 Tolerability 60 bladder carcinoma 60 abacavir lamivudine 60 corticosteroid dexamethasone 60 Pooled Analysis 60 Overactive Bladder OAB 60 INS# [001] 60 ZYBRESTAT 60 interferon gamma 1b 59 AKT inhibitor 59 dependent kinase inhibitor 59 Rituxan rituximab 59 ACTEMRA TM 59 GOUT 59 pediatric acute lymphoblastic 59 PEGylated anti 59 pancreatic islet cell 59 relapsed refractory multiple myeloma 59 treat benign prostatic 59 CR# vcMMAE 59 superficial bladder cancer 59 brivaracetam 59 CCR5 antagonist 59 Selective Internal 59 oral deforolimus 59 Adefovir 59 caspofungin 59 BRAF V#E 59 entinostat 59 relapsed refractory 59 ribavirin Copegus ® 59 inhibitor RG# 59 PROSTVAC ® 59 Pralatrexate 59 EGFR inhibitors 59 Bevacizumab Avastin 59 Fluconazole 59 Phase Ib clinical trials 59 transplantation HSCT 59 ASCO GI 59 Darusentan 59 Epidermal Growth Factor Receptor 59 unresectable 59 Everolimus 59 relapsing remitting multiple sclerosis 59 RSR# 59 icatibant 59 pT2 59 Sorafenib 59 IRX 2 59 GRASPA ® 59 pancreatic prostate 59 NSABP B 59 Pivotal Phase 59 orally bioavailable 59 PSMA ADC 59 Taxotere ® 59 bendamustine 59 myeloid metaplasia 59 zoledronic acid Zometa 59 registrational Phase 59 Platinol ® cisplatin 59 ImClone Erbitux 59 Nitazoxanide 59 doxorubicin docetaxel 59 BAY #-# 59 taxane refractory 59 Interferon alpha 59 Cell Lymphoma CTCL 59 Phase III Clinical Trial 59 Pivotal Study 59 randomized discontinuation trial 59 Vandetanib 59 HERCEPTIN 59 Gleevec imatinib 59 hematological cancers 59 interleukin IL -# 59 humanized anti 59 plus gemcitabine 59 Neupogen ® 59 subependymal giant cell 59 locoregional recurrence 59 lenalidomide Revlimid 59 teriflunomide 59 bosutinib 59 multicenter randomized placebo controlled 59 lung pancreatic 59 vinca alkaloids 59 Pertuzumab 59 PDX pralatrexate 59 TLK# 59 Antiviral Therapy 59 multicenter phase 59 urothelial bladder cancer 59 Fulvestrant 59 daunorubicin 59 PRT# 59 randomized multicenter trial 59 follicular Non Hodgkin 59 trastuzumab Herceptin ® 59 briakinumab 59 Chronic Myelogenous Leukemia 59 Investigational Compound 59 differentiated thyroid 59 liver metastases 59 Zolinza 59 recurrent prostate cancer 59 aripiprazole Abilify 59 clodronate 59 cinacalcet 59 interferon alfa 2a 59 Telbivudine 59 pancreatic colon 59 diagnostic biomarker 59 ORENCIA ® 59 Tyrosine Kinase Inhibitors 59 thymoma 59 catheter occlusion 59 VICTOR E3 59 HER2 overexpression 59 Ofatumumab 59 etanercept Enbrel 59 transplantation HCT 59 Gliadel Wafer 59 Follicular Lymphoma 59 mouse xenograft models 59 elotuzumab 59 #th Annual Interscience 59 allogeneic hematopoietic stem cell 59 small lymphocytic lymphoma 59 mycosis fungoides 59 leukemia CML 59 raloxifene Evista 59 EOquin TM 59 imatinib mesylate 59 orally administered inhibitor 59 chemoradiation therapy 59 gastrointestinal stromal tumors GISTs 59 fallopian tube cancers 59 recurrent squamous cell carcinoma 59 BCG refractory carcinoma 59 paclitaxel poliglumex 59 efaproxiral 59 HER2 Positive Breast Cancer 59 selective kinase inhibitor 59 PI3K/Akt pathway inhibitor 59 topically administered 59 hepatocellular cancer 59 Squalamine 59 tocilizumab 59 Cloretazine 59 eniluracil 59 hepatocellular carcinoma HCC 59 SABCS 59 IV Busulfex 59 Clevudine 59 ErbB2 positive 59 PI3K inhibitor 59 squamous cell carcinoma SCC 59 TACI Ig 59 DU #b 59 tigecycline 59 TELINTRA 59 ABVD 59 Liposomal 59 MVA MUC1 IL2 59 platelet inhibitor 59 metastatic bladder 59 untreated metastatic melanoma 59 infusional 5-FU/LV 59 refractory cutaneous T 59 Fluvastatin 59 Vidaza ® 59 budesonide foam 59 mycophenolate mofetil 59 vorinostat 59 neoadjuvant chemotherapy 59 lung metastases 59 olaparib 59 Patients Receiving 59 HER2 positive breast cancer 59 Adalimumab 59 immunocompetent patients 59 Microalbuminuria 59 Pafuramidine 59 advanced hepatocellular carcinoma 59 Subgroup analysis 59 ibandronate 59 viral kinetics 59 eosinophilic asthma 59 mg/m2 dose 59 relapsed leukemia 59 histone deacetylase HDAC inhibitor 59 hA# 59 Faslodex 59 TKI therapy 59 Stage IIB 59 AACR NCI EORTC 59 ankylosing spondylitis AS 59 Begins Dosing 59 DEB# 59 Elotuzumab 59 MALT lymphoma 59 chemopreventive agent 59 metastatic colon cancer 59 temozolomide Temodar 59 SIR Spheres 59 investigational immunotherapy 59 cytoreduction 59 mutated KRAS gene 59 pulmonary metastases 59 RhuDex ® 59 Torisel 59 NSABP 59 VNP#M 59 Placebo Controlled Trial 59 panobinostat 59 Relapsing Multiple Sclerosis 59 #I TM# 59 transthyretin TTR mediated amyloidosis 59 HuMax CD# 59 solithromycin 59 figitumumab 59 SAR# [004] 59 paclitaxel Taxol R 59 SYN# 59 occlusion PAO 59 Aplidin R 59 Fludara ® 59 Archexin 59 Relapsed Refractory Multiple Myeloma 59 R abatacept 59 Myelodysplastic Syndrome 59 squamous 59 phase IIa clinical 59 Melphalan 59 Sutent sunitinib 59 Mitomycin C 59 Efficacy Trial 59 Boceprevir 59 EFAPROXYN 59 endometrial carcinoma 59 EGFr 59 AS# amonafide L malate 59 IIa trial 59 Telintra 59 SCH # 59 Traficet EN 59 Long Term Efficacy 59 proteasome inhibitor 59 OncoVex 59 adriamycin 59 non squamous NSCLC 59 radezolid 59 Tacrolimus 59 antimitotic 58 docetaxel Injection Concentrate 58 Androgen Independent 58 VFEND 58 Acute Myeloid Leukemia AML 58 Antiviral Activity 58 EURIDIS 58 Adenoma Prevention 58 dose escalation trial 58 CG# [003] 58 ® lenalidomide 58 Panzem R NCD 58 bortezomib Velcade R 58 flutamide 58 BRCA deficient 58 FOLFIRI 58 fistulizing Crohn disease 58 steroid refractory GvHD 58 lintuzumab 58 antiretroviral naïve 58 Vitro Activity 58 CEQ# 58 Aptivus ® 58 nucleotide analogue 58 Actinic Keratosis 58 complement inhibitor eculizumab 58 APTIVUS 58 immunoconjugate 58 Clolar ® 58 Squamous 58 PROVENGE sipuleucel T 58 hormone refractory 58 Cerebril TM 58 NATRECOR ® 58 alefacept 58 pomalidomide 58 EGFR HER2 58 premalignant 58 Phase III Trial 58 thromboembolisms 58 Advanced Renal Cell 58 Gefitinib 58 Adjuvant chemotherapy 58 CLORETAZINE TM VNP#M 58 Benign Prostatic Hyperplasia 58 metastatic adenocarcinoma 58 biochemical relapse 58 homozygous familial hypercholesterolemia 58 Monotherapy 58 Recombinant Human 58 KRAS mutation 58 rituximab Rituxan 58 pelvic malignancies 58 gemcitabine chemotherapy 58 antitumor effect 58 BENICAR HCT 58 3TC lamivudine Epivir 58 Bosutinib 58 vascular disrupting agent 58 CINTREDEKIN BESUDOTOX 58 Targretin 58 YONDELIS R 58 DFMO 58 multicenter Phase 58 FOLPI 58 cancer mCRC 58 Crizotinib 58 darapladib 58 CHOP chemotherapy 58 tarenflurbil 58 2 methoxyestradiol 58 phase Ib 58 Noxafil 58 xenograft models 58 HGS ETR1 mapatumumab 58 interferon alfa 2b 58 antiangiogenic agent 58 CRLX# 58 vismodegib 58 deep venous thromboses 58 renal carcinoma 58 IV metastatic melanoma 58 CML CP 58 HBeAg positive 58 hypomethylating agent 58 Capecitabine 58 Pivotal Clinical Trial 58 Myelodysplastic syndromes MDS 58 non nucleoside 58 HBeAg positive patients 58 IMGN# 58 zoledronate 58 preclinical efficacy 58 TTR amyloidosis 58 ASCUS 58 pemphigus vulgaris 58 TAXOTERE ® 58 PEGPH# 58 antitumor activity 58 Well Tolerated 58 Blinatumomab 58 phase IIb III 58 nab paclitaxel 58 TNFerade TM 58 invasive aspergillosis 58 paclitaxel Taxol ® 58 SPIRIT FIRST 58 temsirolimus Torisel ® 58 recurrent ovarian cancer 58 HRPC 58 Pegylated 58 peritoneal carcinomatosis 58 RCW breast cancer 58 ACTIVE W 58 paricalcitol 58 Cytochrome P# 58 miconazole Lauriad ® 58 crizotinib PF # 58 haematologic malignancies 58 taxane chemotherapy 58 Mantle Cell Lymphoma 58 pharmacokinetics PK 58 irreversible inhibitor 58 TG# [003] 58 plasma kallikrein inhibitor 58 plus dexamethasone 58 HIF PHI 58 antiestrogen 58 canakinumab 58 Golimumab 58 invasive lobular 58 irinotecan oxaliplatin 58 micafungin 58 receiving prophylactic anticoagulation 58 pulmonary metastasis 58 cMET 58 Tyrosine Kinase Inhibitor 58 polymerase inhibitor 58 cell carcinomas 58 azacitidine 58 adjuvant radiation 58 adefovir dipivoxil 58 autologous cellular immunotherapy 58 Randomized Double blind 58 tafamidis 58 pazopanib